This Article Full Text Full Text (PDF) All Versions of this Article: 115/2/204    most recent CIRCULATIONAHA.106.629261v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lindenfeld, J. Articles by Bristow, M. Search for Related Content PubMed PubMed Citation Articles by Lindenfeld, J. Articles by Bristow, M. Related Collections Congestive Ablation/ICD/surgery Pacemaker

(Circulation. 2007;115:204-212.)
© 2007 American Heart Association, Inc.

Heart Failure

Effects of Cardiac Resynchronization Therapy With or Without a Defibrillator on Survival and Hospitalizations in Patients With New York Heart Association Class IV Heart Failure

JoAnn Lindenfeld, MD; Arthur M. Feldman, MD, PhD; Leslie Saxon, MD; John Boehmer, MD; Peter Carson, MD; Jalal K. Ghali, MD; Inder Anand, MD; Steve Singh, MD; Jonathan S. Steinberg, MD; Brian Jaski, MD; Teresa DeMarco, MD; David Mann, MD; Patrick Yong, MSEE; Elizabeth Galle, MS; Fred Ecklund, MA; Michael Bristow, MD, PhD

From the Department of Medicine, University of Colorado Health Sciences Center (J.L., M.R.B.), and Women’s Health Research Center (J.L.), Denver, Colo; Thomas Jefferson Medical College (A.M.F.), Philadelphia, Pa; University of Southern California (Keck School of Medicine) (L.A.S.), Los Angeles; Milton Hershey Medical Center, Penn State School of Medicine (J.B.), Hershey, Pa; Washington DC Veterans Administration (S.S., P.C.), Washington, DC; Wayne State School of Medicine (J.K.G.), Detroit, Mich; Minneapolis Veterans Administration (I.A.), Minneapolis, Minn; San Diego Cardiac Center (B.J.), San Diego, Calif; University of California (T.M.), San Francisco; Cardiovascular Associates and St Mary and Elizabeth Hospital (D.M.), Louisville, Ky; and Boston Scientific (P.Y., E.G., F.E.), St. Paul, Minn.

Correspondence to Dr JoAnn Lindenfeld, Division of Cardiology, University of Colorado Health Sciences Center, 4200 E. Ninth Ave, B-130, Denver, CO 80262. E-mail joann.lindenfeld{at}uchsc.edu

Received April 7, 2006; accepted October 11, 2006.

Background— Cardiac resynchronization therapy (CRT) alone or combined with an implantable defibrillator (CRT-D) has been shown to improve exercise capacity and quality of life and to reduce heart failure (HF) hospitalizations and mortality in patients with New York Heart Association (NYHA) class III and IV HF. There is concern that the device procedure may destabilize these very ill class IV patients. We sought to examine the outcomes of NYHA class IV patients enrolled in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial to assess the potential benefits of CRT and CRT-D.

Methods and Results— The COMPANION trial randomized 1520 patients with NYHA class III and IV HF to optimal medical therapy, CRT, or CRT-D. In the class IV patients (n=217), the primary end point of time to death or hospitalization for any cause was significantly improved by both CRT (hazard ratio [HR], 0.64; 95% CI, 0.43 to 0.94; P=0.02) and CRT-D (HR, 0.62; 95% CI, 0.42 to 0.90; P=0.01). Time to all-cause death and HF hospitalization was also significantly improved in both CRT (HR, 0.57; 95% CI, 0.37 to 0.87; P=0.01) and CRT-D (HR, 0.49; 95% CI, 0.32 to 0.75; P=0.001) Time to all-cause death trended to an improvement in both CRT (HR, 0.67; 95% CI, 0.41 to 1.10; P=0.11) and CRT-D (HR, 0.63; 95% CI, 0.39 to 1.03; P=0.06). Time to sudden death appeared to be significantly reduced in the CRT-D group (HR, 0.27; 95% CI, 0.08 to 0.90; P=0.03). There was a nonsignificant reduction in time to HF deaths for both CRT (HR, 0.68; 95% CI, 0.34 to 1.37; P=0.28) and CRT-D (HR, 0.79; 95% CI, 0.41 to 1.52; P=0.48).

Conclusions— CRT and CRT-D significantly improve time to all-cause mortality and hospitalizations in NYHA class IV patients, with a trend for improved mortality. These devices should be considered in ambulatory NYHA class IV HF patients similar to those enrolled in COMPANION.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				W.H. W. Tang and G. S. Francis The Year in Heart Failure J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2344 - 2351. [Full Text] [PDF]

				C. Leclercq, G. B. Bleeker, C. Linde, E. Donal, J. J. Bax, M. J. Schalij, and C. Daubert Cardiac resynchronization therapy: clinical results and evolution of candidate selection Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I94 - I106. [Abstract] [Full Text] [PDF]

				C Leclercq New guidelines for cardiac resynchronisation therapy: simplicity or complexity for the doctor? Heart, September 1, 2007; 93(9): 1017 - 1019. [Abstract] [Full Text] [PDF]

				W.H. W. Tang and G. S. Francis Cardiac Resynchronization Therapy in New York Heart Association Class IV Heart Failure: It Is All About Selection Circulation, January 16, 2007; 115(2): 161 - 162. [Full Text] [PDF]